LOGIN  |  REGISTER

Encompass Health Announces Date of 2024 Third Quarter Earnings Call

October 10, 2024 | Last Trade: US$100.23 1.11 -1.10

BIRMINGHAM, Ala., Oct. 10, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its third quarter ended Sept. 30, 2024, after the market closes on Monday, Oct. 28, 2024. The Company will host an investor conference call at 10 a.m. ET on Tuesday, Oct. 29, 2024, to discuss its results.

The conference call may be accessed by dialing 800-343-4849 and giving the conference ID EHCQ324. International callers should dial 203-518-9848 and give the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.

A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.

About Encompass Health 

Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 165 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Becker's Hospital Review's 150 Top Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Media contact:
Polly Manuel | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations contact:
Mark Miller | 205-970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB